The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir
D. Jochmans, C. Liu, K. Donckers, A. Stoycheva, S. Boland, S. K. Stevens, C. De Vita, B. Vanmechelen, P. Maes, B. S. Trüeb, N. Ebert, V. Thiel, S. De Jonghe, L. Vangeel, D. Bardiot, , K. Vandyck
This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.
bioRxiv · Jun 7, 2022 · PreprintMicrobiology